Clinical trials: Triple Negative Breast Cancer (TNBC)
Triple-negative Breast Cancer
A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC
Positive circulating tumor DNA(ctDNA) status is associated with worse prognosis in breast cancer, especially triple-negative breast cancer(TNBC).
- Trial name
- Apollo (NCT04501523)
- Testing
- Tislelizumab, capecitabine
- Where
- China
- Volunteers
- 460 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Triple-Negative Breast Cancer (TNBC)
Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC
This study is a phase I/II open-label randomized clinical trial to examine whether administration of isunakinra (EBI-005), a modified recombinant IL1 receptor antagonist, can sensitize human TNBC to the PD1…
- Trial name
- NCT07698106
- Testing
- Group 1-Isunakinra
- Volunteers
- 60 people
- Sponsor
- University Health Network, Toronto
Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC)
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
This is a multicenter, open-label Phase IIa clinical study to evaluate the efficacy and safety of B1962 in the treatment of ad-vanced solid tumors.
- Conditions
- Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
- Trial name
- NCT06724263
- Testing
- B1962
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tasly Biopharmaceuticals Co., Ltd.
Breast Neoplasm
The Study of Trilaciclib Combined With Chemotherapy On The Neoadjuvant Therapy of TNBC
To evaluate the efficacy and safety of trilaciclib combined with standard treatment project as a neoadjuvant treatment for triple negative breast cancer
- Trial name
- NCT05862610
- Testing
- Trilaciclib plus chemotherapy, Chemotherapy
- Volunteers
- 150 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Breast Cancer
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
This is a multicenter, open-label study in participants with triple negative breast cancer (TNBC) to study the safety, tolerability, pharmacokinetics and preliminary efficacy of SC-005.
- Trial name
- NCT03316794
- Testing
- SC-005
- Where
- 8 sites in United States
- Volunteers
- 2 people
- Sponsor
- AbbVie
Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
This phase II trial is studying how well giving entinostat and anastrozole together works in treating postmenopausal women with triple-negative breast cancer that can be removed by surgery.
- Conditions
- Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage I Breast Cancer
- Trial name
- 0927GCC (NCT01234532)
- Testing
- entinostat, anastrozole, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Maryland, Baltimore
Triple Negative Breast Cancer, Inflammatory Breast Cancer Stage IV
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC
This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of bemcentinib (BGB324) in combination with pembrolizumab in participants with previously treated, locally advanced and…
- Trial name
- NCT03184558
- Testing
- Bemcentinib; pembrolizumab
- Where
- 17 sites in United States, Norway and 2 more
- Volunteers
- 29 people
- Sponsor
- BerGenBio ASA
Neoplasms, Breast
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast cancer (Independent of hormone receptor [HR] status, including HR positive [+] and…
- Trial name
- ZEST (NCT04915755)
- Testing
- Niraparib
- Where
- 198 sites in United States, Argentina and 25 more
- Volunteers
- 40 people
- Sponsor
- GlaxoSmithKline
Triple Negative Breast Cancer, Triple Negative Breast Neoplasms
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
This is a single institution, open-label randomized phase 1 trial of neoantigen DNA vaccine alone vs. neoantigen DNA vaccine plus durvalumab in triple negative breast cancer (TNBC) patients following standard of care therapy.
- Conditions
- Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, TNBC - Triple-Negative Breast Cancer, Triple-negative Breast Carcinoma
- Trial name
- NCT03199040
- Testing
- Durvalumab, Neoantigen DNA vaccine, TDS-IM system (Inchor Medical Systems)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Breast Cancer
Breast-Conserving Therapy in Patients With Triple-Negative Breast Cancer
RATIONALE: Triple-negative breast cancer (TNBC) is an aggressive subtype shown to have a high risk of locoregional recurrence (LRR) and distant metastasis (DM).
- Trial name
- NCT02464774
- Testing
- Breast-Conserving Therapy, Mastectomy, Adjuvant Chemotherapy
- Volunteers
- 464 people
- Sponsor
- Xiaoming Xie
Triple Negative Breast Cancer
QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with TNBC who have progressed on or after previous SoC chemotherapy.
- Trial name
- NCT03387085
- Testing
- Aldoxorubicin HCl, N-803, ETBX-011
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- ImmunityBio, Inc.
Triple Negative Breast Cancer (TNBC)
The Neoadjuvant Treatment of Early High-risk Triple Negative Breast Cancer With HRD Positive With Iparomlimab and Tuvonralimab Combined With Olaparib and Paclitaxel
Breast cancer is one of the most common malignant tumors in women, accounting for the first cancer-related death cause in women. In recent years, the incidence has gradually increased, and the trend is younger.
- Trial name
- NCT07187674
- Testing
- Iparomlimab and tuvonralimab combined with olaparib and paclitaxel
- Volunteers
- 20 people
- Sponsor
- Harbin Medical University
Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC)
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
This is a first-in-human Phase 1b, 2-part, multicenter open-label clinical study to evaluate safety and efficacy of a Nectin-4 radiopharmaceutical ([225Ac]Ac-AKY-1189) in patients with locally advanced or metastatic solid tumors…
- Conditions
- Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma, Non Small Cell Lung Cancer
- Trial name
- NCT07020117
- Testing
- [225Ac]Ac-AKY-1189 (therapeutic), [64Cu]Cu-AKY-1189 (imaging)
- Where
- 14 sites in United States
- Volunteers
- 150 people
- Sponsor
- Aktis Oncology, Inc.
Triple Negative Breast Cancer, Breast Cancer
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
The purpose of the study is to evaluate the use of a circulating tumor DNA (ctDNA) assay, ie, a "liquid biopsy," as a tool to identify triple-negative breast cancer (TNBC) patients who will or will not experience benefit from…
- Trial name
- NCT04768426
- Testing
- Capecitabine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Solid Tumors, Triple Negative Breast Cancer (TNBC)
A Study of ADRX-0706 in Select Advanced Solid Tumors
The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patients with select advanced solid tumors.
- Conditions
- Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
- Trial name
- NCT06036121
- Testing
- ADRX-0706
- Where
- 21 sites in United States, China
- Volunteers
- 144 people
- Sponsor
- Adcentrx Therapeutics
Breast Cancer, Triple-Negative Breast Cancer
A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs
This is a phase II, open-labeled, multi-centered, single-arm, investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with apatinib (a VEGFR2 TKI) for neoadjuvant treatment of patients with…
- Trial name
- NCT05556200
- Testing
- Anti-PD-1 monoclonal antibody, VEGFR2 Tyrosine Kinase Inhibitor
- Where
- 4 sites in China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Triple Negative Breast Cancer (TNBC), HER2-Positive Breast Cancer
Home-Based Exercise Program During Neoadjuvant Treatment to Improve Fatigue and Quality of Life in Early HER2-Positive and Triple-Negative Breast Cancer Patients
The goal of this trial is to learn if a home-based exercise program (intervention) reduces fatigue and improves quality of life in adult patients with early breast cancer who are proposed for preoperative chemotherapy.
- Conditions
- Triple Negative Breast Cancer (TNBC), HER2-Positive Breast Cancer, Early Breast Cancer, Cancer-related Fatigue
- Trial name
- HoPEx-Breast (NCT06782698)
- Testing
- Home-based exercise program, Promotion of Healthy Physical Activity
- Where
- Portugal
- Volunteers
- 50 people
- Sponsor
- Centro Hospitalar Universitário de Santo António
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Breast Cancer
A Phase Ib Study of Novel Combination (New) of Low Dose Oral CyclophoSphamide (s) to Potentiate Axatilimab (A) + Retifanlimab (R) in Treating Metastatic Triple Negative Breast Cancer (TNBC)
The goal of this clinical research study is to find the best dose of the drugs cyclophosphamide and axatilimab that can be given in combination with the standard dose of retifanlimab to patients with metastatic TNBC.
- Trial name
- NCT06959537
- Testing
- Cyclophosphamide, Axatilimab (SNDX-6352), Retifanlimab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Triple-negative Breast Cancer
A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.
To evaluate the clinical efficacy and safety of oral all-trans retinoic acid in combination with toripalimab in patients with locally advanced, recurrent, or metastatic triple-negative breast cancer who had failed second-line and…
- Trial name
- NCT06371274
- Testing
- ATRA, Toripalimab
- Where
- China
- Volunteers
- 29 people
- Sponsor
- First Affiliated Hospital of Zhejiang University